30/03/2021 - 14:05

Positive signs for PharmAust K9 anti-cancer drug trial

30/03/2021 - 14:05


Save articles for future reference.

ASX and Frankfurt Stock Exchange-listed PharmAust has unveiled encouraging initial results from the continuing phase IIb clinical trial of its anti-cancer drug, Monepantel on pet dogs suffering from B-cell lymphoma. The Perth-based company says the first five dogs who have undergone treatment with Monepantel across five participating test sites show “minimal side effects”.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options